Filana Therapeutics, Inc. (FLNA) · Nov 5, 2026 · Earnings
In line — Q3 net loss $0.22/share vs $0.22 prior year; no reliable published consensus
Filana’s third-quarter earnings reaffirm a first-quarter 2027 Phase 2a start, while restricted cash and ongoing losses narrow the funding picture.
Filana is a single-asset biotech trying to move simufilam into a Phase 2a study for TSC-related epilepsy after the FDA removed the clinical hold. That regulatory unlock was already disclosed on September 22, 2026, so this filing mainly confirms execution timing and updates the cash picture rather than creating a new clinical catalyst.
The development program remains on track, but this is confirmation rather than a fresh breakthrough. Filana still expects to begin screening patients in the first quarter of 2027 for a roughly 40-patient, 13-site randomized study. 〔0〕 The October publication adds supportive preclinical biology, but it does not provide human efficacy evidence or change the trial’s regulatory status.
Quarterly financial performance was broadly routine. Third-quarter net loss was $10.7 million, or $0.22 per share, essentially unchanged from the prior year, while operating expenses fell modestly. With no dependable published consensus for this small biotech, the cleanest benchmark is the company’s own prior-year quarter: financially, this was in line rather than a meaningful beat.
| Metric | Q3 2026 | Q3 2025 | 2026 outlook / balance |
|---|---|---|---|
| R&D expense (Financial Results) | $3.9M (-2%) | $4.0M | |
| G&A expense (Financial Results) | $7.4M (-6%) | $7.9M | |
| Net loss (Income Statement) | $10.7M | $10.8M | |
| Net loss per share (Income Statement) | $0.22 | $0.22 | |
| Cash and equivalents (Balance Sheet) | $47.0M | ||
| Restricted cash (Balance Sheet) | $31.25M | ||
| Operating cash use (Financial Results) | $11M-$15M H2 | ||
| Year-end cash estimate (Financial Results) | $38M-$42M |
The balance sheet is the more important new read. Cash and equivalents fell to $47.0 million from $95.5 million at year-end, while $31.25 million was placed into escrow for potential securities-litigation settlement and is shown as restricted cash. The company has no debt, but the escrow materially reduces cash available for development, and the filing projects another $11 million to $15 million of operating cash use in the second half.
Bottom line: The filing keeps Filana’s Phase 2a story intact, but mostly confirms a catalyst the market already knew about. The modestly positive clinical progress is offset by unchanged losses and a thinner usable-cash position after the litigation escrow, making this a mixed, limited-impact update.
Phase 2a patient screening, expected Q1 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!